No Predicate, High Risk, or Just Incomplete? Route the FDA Request First
Compare 510(k), De Novo and PMA by classification question, predicate and evidence object before a regulatory-service team promises a submission route.
Signals to watch
- A team asks for a 510(k) quote but cannot name a classification regulation or predicate device
- A novel low-to-moderate-risk device is described as having no predicate and needs a classification discussion
- A high-risk device request mentions clinical evidence but not an approved PMA, supplement type or device change
Choose the discovery owner before choosing 510(k), De Novo or PMA. A 510(k) asks whether a device is substantially equivalent to a legally marketed predicate. De Novo asks FDA to classify an eligible novel device for which there is no legally marketed predicate. PMA evaluates reasonable assurance of safety and effectiveness for applicable Class III devices. An incomplete Telegram request proves none of those starting conditions.
Definition: a premarket route is the FDA decision process applicable to a device and its proposed US marketing. It is not a price tier. Classification, intended use, indications, technological characteristics, predicate status, risk and prior FDA decisions determine which regulatory questions must be resolved.
Three messages arrive; none is ready for a quote
A regulatory consultancy business-development lead follows authorised Telegram groups for medtech founders, device engineers, clinical teams and US market-entry advisers. During one morning, the lead sees this illustrative composite:
“Need 510k for a wearable, launch Q1. Who can do fast?”
“New diagnostic, no predicate we can find.”
“Class III change, clinical data already available.”
These are not real prospects or complete submission briefs. “Wearable” does not define intended use. “No predicate we can find” is not an FDA classification conclusion. “Class III change” does not identify the approved PMA, supplement object or change.
Waiting a day may mean the team hires a writer before it has a classification strategy, making the first deliverable unusable. The commercial Signal is therefore a request for route discovery with a stated launch pressure—not a confirmed 510(k), De Novo or PMA engagement.
The decision objects are different
| Route | FDA decision object | Evidence that starts useful discovery | Common missing fact |
|---|---|---|---|
| 510(k) | whether the new device is substantially equivalent to a legally marketed predicate | intended use, indications, technology, classification regulation, product code and predicate comparison | predicate or meaningful difference analysis |
| De Novo | whether an eligible novel device can receive Class I or II classification with applicable controls | device description, benefits and risks, proposed classification, general and special controls, and predicate search | why no existing classification or predicate fits |
| PMA | whether valid scientific evidence supports reasonable assurance of safety and effectiveness | Class III basis, device design, nonclinical and clinical evidence, manufacturing information and prior approvals | exact original PMA or supplement object |
The FDA’s 510(k) page describes substantial equivalence to a legally marketed predicate. A predicate is not merely a similar product sold online; it must have the right legal status, and differences in intended use or technology require analysis.
The De Novo page addresses eligible novel devices for which there is no legally marketed predicate. FDA describes both a direct request and a request after a not-substantially-equivalent decision. De Novo is not shorthand for “innovative” and does not remove the need for benefit-risk evidence and controls.
The PMA page describes PMA as the most stringent type of device marketing application. Its question is safety and effectiveness, not substantial equivalence. An approved PMA device change may involve a supplement rather than a new original PMA, so the approval record and proposed modification matter.
Route the first call by what is missing
For the wearable message, ask for a one-page device description, intended use, indications for use, users, environment, technology and current FDA classification research. If the sender can name a product code and predicate, a 510(k) specialist can test the comparison. If not, classification discovery comes first.
For the novel diagnostic, preserve the predicate-search terms and candidate devices. Ask what makes each candidate unsuitable, what risks have been identified and what controls could mitigate them. That allows a De Novo specialist to review an evidence gap rather than accept the sender’s “no predicate” conclusion.
For the Class III change, retrieve the approval number, owner, device version, proposed change, prior supplements and available study reports. Only then can a PMA specialist distinguish a new application, supplement, annual-report item or another regulatory question.
The FDA device-record source router helps recover classification, clearance, De Novo and approval records. If the request concerns cybersecurity material rather than the whole route, use the FDA 524B evidence chain. A quality-system readiness issue belongs in the QMSR gap-assessment intake.
Price follows scope; route does not follow budget
A useful scoping note states the requested market decision, current classification hypothesis, evidence already held, unresolved route questions and the next bounded deliverable. That deliverable might be classification research, predicate landscape review, a De Novo evidence-gap assessment or PMA change assessment.
It should not promise clearance, grant or approval. FDA review outcomes and timelines depend on the actual device, submission quality, interactions and current programme requirements. Likewise, a sender’s budget or desired launch date cannot turn an ineligible route into an eligible one.
TOP Prospect can retain original fragments, times, group sources, duplicate relationships, summaries and human review notes from authorised groups. The current matching-target interface saves configuration but does not automatically create candidates. It cannot search confidential FDA files, determine classification, verify a predicate, submit an application, contact authors or predict an FDA decision. The public Signal workflow keeps that human boundary explicit.
Key facts
- 510(k) is built around substantial equivalence to a legally marketed predicate.
- De Novo provides a classification route for eligible novel devices without a legally marketed predicate.
- A direct De Novo request does not require a prior 510(k) not-substantially-equivalent decision.
- PMA evaluates reasonable assurance of safety and effectiveness for applicable Class III devices.
- Device class alone does not fully establish the submission route; exemptions, product codes and device-specific requirements matter.
- Intended use, indications, technology and prior FDA records remain essential across all three discovery paths.
FAQ
Is 510(k) always the route for a Class II device?
No. Many Class II devices require 510(k), but exemptions and other routes exist. The current classification regulation, product code, intended use and applicable FDA requirements must be checked.
Is De Novo only for devices that failed a 510(k)?
No. FDA describes a direct De Novo request for eligible novel devices without first submitting a 510(k), as well as the route following a not-substantially-equivalent determination.
Does PMA simply mean a more expensive 510(k)?
No. PMA is FDA’s most stringent premarket review and evaluates reasonable assurance of safety and effectiveness for applicable Class III devices; 510(k) focuses on substantial equivalence.
What is the first useful question for a service lead?
Ask for intended use, indications, technology, proposed classification, product code, predicate search and prior FDA interaction before assigning a pathway specialist.
Reviewed by TOP Prospect Editorial Team on 19 August 2026 against current FDA 510(k), De Novo, PMA and device-classification pages. This routing article is not regulatory or legal advice; the actual device record and current FDA requirements control.
Frequently asked questions
Is 510(k) always the route for a Class II device?
No. Many Class II devices require 510(k), but exemptions and other routes exist. The current classification regulation, product code, intended use and applicable FDA requirements must be checked.
Is De Novo only for devices that failed a 510(k)?
No. FDA describes a direct De Novo request for eligible novel devices without first submitting a 510(k), as well as the route following a not-substantially-equivalent determination.
Does PMA simply mean a more expensive 510(k)?
No. PMA is FDA’s most stringent premarket review and evaluates reasonable assurance of safety and effectiveness for applicable Class III devices; 510(k) focuses on substantial equivalence.
What is the first useful question for a service lead?
Ask for intended use, indications, technology, proposed classification, product code, predicate search and prior FDA interaction before assigning a pathway specialist.
Sources and further reading
How a Signal worth attention is found
See how Top Prospect finds and organizes Signals worth checking, keeps the original Telegram context, removes duplicates, and helps you decide what to review first. You decide whether to follow up and what to do next.
